Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The German series proving subtitles can be sexy — and wildly addictive - 2Parents who delay baby's first vaccines also likely to skip measles shots
- 3Pick Your Number one sort of blossom
- 4FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- 5Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- Israel reports second missile fire from Yemen since start of Iran war
- Medical team successfully delivers baby and removes massive tumor
- Barry Manilow to have surgery for early-stage lung cancer and postpones January concerts
- Share your number one city visit transport that leaves a mark on the world wake up!
- The most effective method to Guarantee Thorough Inclusion in Senior Protection.
- 5 State of the art Advancements in Computer generated Simulation
- Why screening for the deadliest cancer in the U.S. misses most cases
- Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
